Table 1.

Descriptive data of the 3 independent patient cohorts TuCP1, TuCP2, and TCGA

TuCP1TuCP2TCGA
No. of patients%No. of patients%No. of patients%
No. of patients20764502
SexMale14771.03757.833065.7
Female6029.02742.217234.3
AgeaMedian (range)64 (17–90)64 (36–88)61 (26–90)
Tumor size (cm)
 Median (range)4.5 (0.3–12.5)5.5 (1.4–16)b
T114067.63453.124949.6
20069.46412.7
36732.42437.517835.5
4112.2
Nx/020498.65687.548496.4
1/231.4812.5183.6
M018187.45179.742584.7
12612.61320.37715.3
G13416.41421.9c112.2d
214871.54164.1c21342.4d
3/42512.1914.1c27254.2d
L020096.66195.3b
173.434.7b
V015775.84671.9cb
14923.71726.6cb
210.511.6cb
R019594.2d6093.8cb
1115.3d46.3cb
Tumor necrosis
 Yes7938.2914.128256.2
 No12861.85585.922043.8
Sarcomatoid differentiation
 Yes104.846.3cb
 No19795.26093.8cb
Follow-up time (y)
 Median (range)5.9 (0–18)2.3 (0–4.7)3 (0–10)
Recurrence
 Yes2612.634.7b
 No18187.46195.3b
Overall survival
 Deceased7536.2d1218.833767.1d
 Alive12861.8d5281.216432.7d
Cancer-specific survivale
 Cancer-related death4220.3d1218.8b
 Alive/noncancer-related death16177.8d5281.2b

Abbreviations: G, grading; L, invasion into lymph vessels; M, distant metastasis; N, regional lymph nodes; R, resection status; T, primary tumor; V, invasion into veins.

  • aAge at surgery for TuCP1 and TuCP2, age at initial pathologic diagnosis for TCGA.

  • bParameters were not available for the TCGA cohort.

  • cPercentages do not sum up to 100% due to rounding.

  • dPercentages do not sum up to 100% because of missing values.

  • eOf note, all patients in the TuCP2-cohort died due to ccRCC; therefore, cancer-specific survival and overall survival is identical in this cohort.